CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
复制标题
CAMSAP1 突变与接受铂类化疗的小细胞肺癌患者的预后改善相关
DOI：
10.3389/fcell.2021.770811
复制
发表时间：
2021
影响因子：
5.5
通讯作者：
Shen W
中科院分区：
文献类型：
--
作者：
Yi Y;Qiu Z;Yao Z;Lin A;Qin Y;Sha R;Wei T;Wang Y;Cheng Q;Zhang J;Luo P;Shen W
以铂类为基础的化疗是小细胞肺癌（SCLC）的一线治疗。然而，由于患者对药物产生耐药性，大多数患者会复发，他们的癌症可能无法治疗。近年来大量研究发现，各种癌症的铂类药物敏感性受特定基因突变的影响，因此通过本研究，我们试图在SCLC患者中找到一种有效的遗传生物标志物，以指示其对铂类药物的敏感性。为此，我们首先分析了两个队列的全外显子组测序（WES）和临床数据，以发现与SCLC患者预后和铂类药物敏感性相关的基因突变。使用的队列为珠江队列（N = 138）和乔治等人报告的队列（N = 101）。然后，我们进行了基因集变异分析（GSVA）和基因集富集分析（GSEA），以研究这些基因突变影响患者预后和铂类药物敏感性的可能分子机制。我们发现，对于SCLC患者，CAMSAP 1突变可以激活抗肿瘤免疫，介导肿瘤细胞凋亡，抑制上皮-间质转化（EMT），改善预后，提高铂类药物敏感性，表明CAMSAP 1突变可能是SCLC铂类药物敏感性和患者预后的潜在生物标志物。
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
登录
查看更多内容
影响因子：
64.8
作者：
Helmink BA;Reddy SM;Gao J;Zhang S;Basar R;Thakur R;Yizhak K;Sade-Feldman M;Blando J;Han G;Gopalakrishnan V;Xi Y;Zhao H;Amaria RN;Tawbi HA;Cogdill AP;Liu W;LeBleu VS;Kugeratski FG;Patel S;Davies MA;Hwu P;Lee JE;Gershenwald JE;Lucci A;Arora R;Woodman S;Keung EZ;Gaudreau PO;Reuben A;Spencer CN;Burton EM;Haydu LE;Lazar AJ;Zapassodi R;Hudgens CW;Ledesma DA;Ong S;Bailey M;Warren S;Rao D;Krijgsman O;Rozeman EA;Peeper D;Blank CU;Schumacher TN;Butterfield LH;Zelazowska MA;McBride KM;Kalluri R;Allison J;Petitprez F;Fridman WH;Sautès-Fridman C;Hacohen N;Rezvani K;Sharma P;Tetzlaff MT;Wang L;Wargo JA
通讯作者：
Wargo JA
影响因子：
10.7
作者：
Baines, Anthony J.;Bignone, Paola A.;Phillips, Gareth W.
通讯作者：
Phillips, Gareth W.
影响因子：
64.8
作者：
Cabrita, Rita;Lauss, Martin;Jonsson, Goran
通讯作者：
Jonsson, Goran
DOI：
10.1073/pnas.1404133111
发表时间：
2014-04-22
影响因子：
11.1
作者：
Hendershott, Melissa C.;Vale, Ronald D.
通讯作者：
Vale, Ronald D.
影响因子：
8.8
作者：
Chuang M;Goncharov A;Wang S;Oegema K;Jin Y;Chisholm AD
通讯作者：
Chisholm AD